Evaluation of the new INNOVANCE (R) PFA P2Y cartridge in patients with impaired primary haemostasis

Koessler, Juergen and Ehrenschwender, Martin and Kobsar, Anna and Brunner, Kirsten (2012) Evaluation of the new INNOVANCE (R) PFA P2Y cartridge in patients with impaired primary haemostasis. PLATELETS, 23 (8). pp. 571-578. ISSN 0953-7104,

Full text not available from this repository. (Request a copy)

Abstract

Recently, the INNOVANCE (R) PFA P2Y (P2Y) cartridge of the PFA-100 (R) system (Siemens Healthcare Diagnostics, Marburg, Germany) has been developed for the monitoring of adenosine diphosphate (ADP) P2Y(12) receptor inhibition in patients under dual antiplatelet therapy. The aim of this study was to evaluate the influence of pre-existing defects in primary haemostasis on the P2Y cartridge independent from specific antiplatelet medication. Therefore, the closure time (CT) of the P2Y cartridge was measured in a cohort of 176 patients with assumed bleeding disorders and compared with the results of established methods for the assessment of primary haemostasis. Von Willebrand disease (VWD) was found in 25 patients (14%). The detection rate of the P2Y cartridge regarding VWD was 64% and lower compared to the two conventional cartridges (collagen/epinephrine cartridge, CEPI, 80%; collagen/ADP cartridge, CADP, 76%). In the subgroup of VWD patients with VWF:RCo < 60 IU/dL (n = 22), the correlation analysis and the inter-rater agreement revealed only limited accordance with the two established cartridges. The correlation with the CADP cartridge (C-r = 0.767, R-2 = 0.461; Kappa = 0.41) was higher than the correlation with the CEPI cartridge. Except for severe forms, platelet function disorders (9 patients, 5%) did not prolong the CT of the P2Y cartridge. Interestingly, the P2Y cartridge was less interference-prone to unspecific medications (23 patients, 13%). As the main conclusion, it must be taken into account that low von Willebrand factor activity can significantly influence the CTs of the P2Y cartridge when using it for the monitoring of antiplatelet therapy.

Item Type: Article
Uncontrolled Keywords: VON-WILLEBRAND-DISEASE; PLATELET-FUNCTION; SHEAR STRESS; PFA-100(R); DIAGNOSIS; MANAGEMENT; THERAPY; VWD; Antiplatelet therapy; bleeding disorder; INNOVANCE (R) PFA P2Y; PFA-100 (R) cartridge; primary haemostasis; von Willebrand disease
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene
Depositing User: Dr. Gernot Deinzer
Date Deposited: 22 May 2020 09:16
Last Modified: 22 May 2020 09:16
URI: https://pred.uni-regensburg.de/id/eprint/19426

Actions (login required)

View Item View Item